Global Veterinary Healthcare Market 2018 Trends, Research, Analysis & Review Forecast 2021

PUNE, MAHARASHTRA, INDIA, May 10, 2018 / — Global Veterinary Healthcare Industry

New Study on “2018-2021 Veterinary Healthcare Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” added to Wise Guy Reports Database

The Global Veterinary Healthcare Market was worth $27 billion in 2016 and estimated to be growing at a CAGR of 7.94%, to reach $39.56 billion by 2021. Veterinary medicine can be defined as the science associated with the diagnosis, treatment and prevention of diseases in animals. The scope of Veterinary medicine is broad covering various animal species both domestic and wild. The increasing importance for the production of livestock animals is generating growth in the animal healthcare market. Ever increasing population, stable economy is expected to result in increased demand for protein rich foods, especially in the developing countries.

Try Sample Report @

Increased love for pets leading to an upsurge in the number of animal ownerships, increasing awareness among the people about animal health and very few requirements for animal health drugs approval are the major factors driving the market for Veterinary healthcare. Growing number of foodborne diseases is also fuelling the animal healthcare market. However increasing regulation on antibiotics is expected to remain a major restraint for the market. Apart from that increasing costs regulation related to animal testing is also a major hurdle for the growth of animal healthcare market.

Global Veterinary Healthcare market is segmented by animal type and product. On the basis of animal type market is segmented into farm animals and companion animals. Farm animals are further sub segmented into cattle, swine, fish, sheep and poultry whereas companion animals are sub segmented as dogs, and cats. Based on product the marketed is segmented into Vaccines, feed additives and pharmaceuticals. Feed additives are further sub-segmented into Nutritional feed additives and Medicinal feed additives. Nutritional feed additives include amino acids, vitamins and minerals. Medicinal feed additives on the other hand include hormones, probiotics, immune-modulators, enzymes and prebiotics. Pharmaceutical products mainly comprise of ectoparasiticides, endoparasiticides, antibiotics, anti-inflammatories, endectocides, and medicines for reproductive problems.

Based on Geography Global Veterinary Healthcare market is analyzed under various regions namely North America, Europe, Asia-Pacific, Latin America and Middle-East and Africa. Europe and North America are the dominating markets for veterinary healthcare accounting for a combined share of around 60% of the market due to a number of pet owners. Asia-Pacific is one of the major producers of animal meat and estimated to be the fastest growing region during the forecast period.

Some of the major companies covered in the report are Merck & Co., Inc., Bayer AG, Boehringer Ingelheim GmbH, Cargill, Inc., Ceva Santé Animale, Novasep, Eli Lilly and Company, Koninklijke DSM N.V, Novartis AG, Nutreco N.V., Sanofi S.A., SeQuent Scientific Ltd., Virbac S.A., Vétoquinol S.A. and Zoetis Inc.

For Detailed Reading Please visit WiseGuy Reports @

 Some points from table of content:

1.1 Market Definition

1.2 Study Deliverables

1.3 Base Currency, Base Year and Forecast Periods

1.4 General Study Assumptions

Research Methodology
2.1 Introduction

2.2 Research Phases

2.2.1 Secondary Research

2.2.2 Primary Research

2.2.3 Econometric Modelling

2.2.4 Expert Validation

2.3 Analysis Design

2.4 Study Timeline

3.1 Executive Summary

3.2 Key Inferences

3.3 New Developments

Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers

4.2 Market Restraints

4.3 Key Challenges

4.4 Current Opportunities in the Market

Market Segmentation
5.1 By Animal Type

5.1.1 Farm Animals Cattle Swine Fish Sheep Poultry

5.1.2 Companion Animals Dogs Cats

5.2 By Product

5.2.1 Vaccines

5.2.2 Feed Additives Nutritional Feed Additives Medicinal Feed Additives

5.2.3 Pharmaceuticals

Geographical Analysis
6.1 North America

6.1.1 Introduction

6.1.2 United States

6.1.3 Canada

6.2 Europe

6.2.1 Introduction

6.2.2 U.K

6.2.3 Spain

6.2.4 Germany

6.2.5 Italy

6.2.6 France

6.3 Asia-Pacific

6.3.1 Introduction

6.3.2 China

6.3.3 India

6.3.4 Japan

6.3.5 South Korea

6.4 Latin America

6.4.1 Introduction

6.4.2 Brazil

6.4.3 Mexico

6.4.4 Rest of Latin America

6.5 Middle East & Africa

6.5.1 Introduction

6.5.2 Middle-East

6.5.3 Africa


For more information or any query mail at

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn:

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire

InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD

STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users

LITTLE ROCK, ARKANSAS, USA, May 9, 2018 / — InterveXion announces the enrollment of the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200. STAMPOUT will be a Phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users. InterveXion has previously conducted a robust nonclinical evaluation of the pharmacology, toxicology, and pharmacodynamics of IXT-m200, and has completed an initial Phase 1 clinical safety study with this investigational product.

IXT-m200, a monoclonal antibody that specifically binds methamphetamine in the blood, is being developed as a pharmacological treatment for use in conjunction with behavioral therapies. IXT m200 is expected to alter methamphetamine pharmacokinetics in human subjects resulting in reduced or blocked subjective effects that reinforce methamphetamine use. STAMPOUT will provide proof-of-concept that IXT m200 can alter methamphetamine disposition. This will be the first clinical study in methamphetamine users of a biological medication developed specifically for patients with methamphetamine use disorders.

Methamphetamine addiction is a serious global healthcare burden, with over 400,000 people addicted to methamphetamine in the US alone, and an overall cost to the US healthcare system in excess of $20B annually. There are no pharmacologic therapies for methamphetamine addiction, and current treatment is limited to counseling and behavioral modification. There is a sizable population of treatment-seeking methamphetamine users, with >100,000 patients admitted annually to US treatment centers for methamphetamine abuse.

“Our extensive preclinical data demonstrate that IXT-m200 can meaningfully alter the pharmacokinetics and pharmacodynamics of methamphetamine.”, noted Dr. W. Brooks Gentry, InterveXion’s Chief Medical Officer. “The STAMPOUT study will demonstrate whether these effects translate into methamphetamine users, and we are excited to have the study underway”.

STAMPOUT is funded by a three-year $8 million grant award from the National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA). A sub-award to the University of Arkansas for Medical Sciences (UAMS) is part of the grant and funds researchers who are both founders of the company and also prominent UAMS leaders. InterveXion is a BioVentures, LLC, client company housed on the UAMS campus in Little Rock, AR.

For more information on this study, visit:

InterveXion is a pharmaceutical company whose mission is to discover and advance innovative medications that reduce the impact of human suffering on individuals and communities. Its vision is to be a leader in the development of antagonist therapies that neutralize toxins in the body and thereby improve patient health. InterveXion’s first medications are a monoclonal antibody and an active vaccine for treating methamphetamine abuse. For more information, contact STAMPOUT is supported by NIH/NIDA under Award Number U01DA045366. The content of this release is solely the responsibility of InterveXion and does not necessarily represent the official views of the National Institutes of Health.

Misty Stevens
InterveXion Therapeutics
email us here

Source: EIN Presswire

Arecont Vision Releases ConteraVMS, ConteraWS Web Services, & ConteraCMR Cloud Managed Recorders

Arecont Vision Contera Video Surveillance NVR VMS Web services

AV Total Video Surveillance Solution with Contera

Arecont Vision announces availability of Contera video surveillance software, web services, & cloud-managed video recorders for customer ordering

With Contera, Arecont Vision now offers a complete video surveillance solution with megapixel cameras, VMS, recorders, and cloud services.”

— Brad Donaldson, VP, Product Development

LOS ANGELES, CA, UNITED STATES, May 9, 2018 / — Arecont Vision®, the industry leader in IP-based megapixel camera and video surveillance solutions, announces the immediate availability of the Contera® line of video surveillance software, cloud-managed web services, and cloud-managed video recorders for customer ordering. Contera offers a complete, integrated solution for traditional local or advanced cloud-managed video surveillance project requirements.

“Those visiting our ISC West booth in Las Vegas were quite excited about the Contera Total Video Surveillance Solution when it was unveiled and demonstrated at the 2018 event in April,” said Brad Donaldson, Vice President of Product Development for Arecont Vision. “Our initial pre-release customers have validated the Contera solution, and we are now announcing availability to the security and surveillance industry.”

The Contera Total Video Surveillance Solution is composed of megapixel cameras (Arecont Vision Mega™ and ConteraIIP® single- and multi-sensor families), advanced video management system software (ConteraVMS®), a range of video recorders and NVRs (ConteraCMR®), and powerful cloud-based web services (ConteraWS®). ConteraVMS, ConteraWS, and ConteraCMR are now available. ConteraMobile® is also available from the Apple and Google app stores. The final component of the solution, Contera megapixel cameras, will become widely available in coming weeks.

The ConteraVMS offers Standard (16 cameras), Premium (64 cameras), and Professional (128 cameras) license choices with a range of advanced features. Arecont Vision systems integrators can download a Contera 30 Day Free Trial License. End users can obtain a trial license through their systems integrator.

ConteraWS (web services) enables recording to occur locally for reliability and optimized frame rates, while leveraging remote management and uploading clips of interest securely in the cloud. This eliminates the need for local administration and allows secure access and administration from anywhere.

The ConteraCMR series offers four customizable cloud management recorder platform choices. They are the ConteraCMR NVR appliance (2U form factor, 8 or 16 PoE ports, up to 20TB storage), Compact Desktop NVR Server (maximum of 32 channels and 24TB storage with optional RAID 5), Compact NVR server (2U form factor, maximum of 64 channels and 24TB storage with optional RAID 5), and the High Performance NVR Server (extended 2U form factor, maximum of 128 channels and 80TB storage with optional RAID 5).

All Arecont Vision products include a 3-year manufacturer’s warranty.

To learn more about the Contera Total Video Surveillance Solution, please visit Arecont Vision online at You may also contract your local Arecont Vision sales team (, or speak with our headquarters team at +1.818.937.0700 (select option 3), or via email at

# # #

Arecont Vision is the leading US-based manufacturer of high-performance IP cameras and video surveillance solutions. The company offers two-megapixel camera families – the Mega series includes Made in USA, cyber-secure MicroBullet®, MicroDome®, MegaBall®, MegaDome®, MegaVideo®, MegaView®, and SurroundVideo® models, plus the world-class Contera® series dome and bullet models. Both camera families offer single- and multi-sensor choices that are integrated with the ConteraVMS® (video management system), ConteraWS® (web services), and the ConteraCMR® (cloud-managed video recorder) series for traditional or cloud-based video surveillance solutions. Arecont Vision supports integration with leading 3rd party products through the MegaLab™ and via ONVIF compliance.

Jeff Whitney / VP Marketing / Arecont Vision
Phone: +1.818.937.0477

Jeff N Whitney
email us here

Source: EIN Presswire

Eric Ansart of Lympha Press USA to receive LE&RN Impact Award at #DCLymphWalk, Lincoln Memorial, 5/12

Eric Ansart, President of Lympha Press USA

Eric Ansart, President of Lympha Press USA

Wlliam Repicci and Kathy Bates to head up DC Lobby Day and DC LymphWalk

Ansart and Lympha Press USA team to lobby for #LymphaticFunding on 5/11 and participate in 5/12 Walk

The LE&RN Impact Award recognizes Lympha Press’s contributions to education and advocacy on behalf of the LE and LD communities.”

— Eric Ansart, President of Lympha Press USA

NEW YORK, NY, USA, May 9, 2018 / — The Lymphatic Education & Research Network (LE&RN) has announced that Eric Ansart, President of Lympha Press USA, will be given the LE&RN Impact Award at the inaugural DC/VA Walk to Fight Lymphedema & Lymphatic Diseases at the Lincoln Memorial, on Saturday, May 12.

Ansart and Lympha Press USA are long-time supporters of LE&RN and are currently spearheading the effort to create LE&RN's Physician Seminars in Lymphatic and Vascular Disease Diagnosis and Treatment, organized in conjunction with Shoosh Crotzer of Lymphedema Seminars. The continuing medical education (CME) seminars, designed to educate the medical community on lymphedema (LE) and lymphatic diseases (LD), will debut at The Harvard Club in Boston on July 21, 2018.

“I am honored to receive the LE&RN Impact Award, which recognizes Lympha Press’s contributions to education and advocacy on behalf of the LE and LD communities,” said Ansart. “I’ll be in DC, along with a team of Lympha Press employees, to support LE&RN Lobby Day on Friday, May 11, and to support the DC LymphWalk on Saturday.”

“As a company, we are committed to improving the lives of the people we serve,” Ansart continued. “Lympha Press employees develop lasting relationships with our customers and their long-term success. It is what drives our continuing dedication to this cause. The movement has come a long way. However, far too often we hear from patients who were misdiagnosed or not diagnosed for many years. To us, this is unacceptable. We must do more to educate and to dedicate money for research. This is why we will be joining LE&RN in DC this week; we believe that solutions are possible.”

“Eric and the team at Lympha Press USA are wonderful examples of corporate citizenship,” said William Repicci, LE&RN President & CEO. “We are fortunate to have them as partners in the fight against LE and LD. As we come together, we will change the lives of the millions who struggle with these diseases on a daily basis. DC promises to be a turning point in this movement. And we hope that everyone will find a way to lend their support.”

To sign up to walk in support of the 10 million Americans and 170 million worldwide who are battling this lymphedemic™, just register at Social media activists should use hashtags #DCLymphWalk and #DCLymphLobby.

LE&RN thanks National Series Walk sponsors BSN medical (Premier National Sponsor), Tactile Medical (Presenting Sponsor), Lympha Press USA, BioCompression Systems, Juzo, ImpediMed/L-Dex, Eiger BioPharmaceuticals, Sigvaris, MediUSA, Herantis Pharma, L&R USA Inc., and LympheDIVAS.

About LE&RN
Founded in 1998, the Lymphatic Education & Research Network (formerly LRF) is a 501(c)(3) not-for-profit organization whose mission is to fight lymphatic disease and lymphedema through education, research and advocacy. LE&RN provides valuable educational resources for the millions of people who suffer from lymphedema and lymphatic disease. LE&RN fosters and supports research that can deepen the medical community's understanding of the lymphatic system. For more information about lymphatic diseases or the Lymphatic Education & Research Network, please visit or call (516) 625-9675.

Laura Farrell
Lymphatic Education & Research Network
(516) 625-9675
email us here

Source: EIN Presswire

Kiss Insomnia Goodbye with PEGASI Light Therapy Smart Glasses

PEGASI Light Therapy Smart Glasses (Frontview)

PEGASI Light Therapy Smart Glasses (Frontview)

PEGASI Light Therapy Smart Glasses Mobile App

PEGASI Light Therapy Smart Glasses Mobile App

These High-Tech Glasses Treat Sleeping Disorders without Medicine

SAN FRANCISCO, CA, US, May 9, 2018 / — GenHigh, a global leader in quality, innovative consumer products, is pleased to announce the debut of PEGASI Smart Sleep Glasses. The company will showcase its latest product at PEPCOM’s Digital Experience on May 10, 2018 at the Metreon City View (135 4th Street) in the SoMa district of San Francisco.

PEGASI Smart Sleep Glasses is a pair of smart lenseless glasses that improve the users sleep quality with physical light therapy. The unique dual-wavelength light stimulates the nervous system with a signal that regulates melatonin secretion and improves sleep quality. With PEGASI the user will fall asleep faster and have better sleep quality with only 30 minutes of use a day for 7 days.

Light therapy has been proved by NASA to improve an astronaut’s sleep quality in space. PEGASI now brings this innovative technology to the public to help everyone who suffers from sleeping disorders. PEGASI is embedded with lights that reside on the inner edges of the glasses to emit a soft green hue when activated. This serves to produce certain wavelengths of light which can affect sleep quality by stimulating the hypothalamus gland responsible for synchronizing circadian rhythm and the secretion of melatonin which aids sleep.

It has been found that circadian rhythms can be trained to be shorter or longer, thus affecting hours of sleep. PEGASI hopes to train circadian rhythms among insomniacs to promote a more regular sleep cycle in a non-invasive, non-medical way. While everyone may deal with some type of short-term insomnia, there are some who suffer from long-term bouts. This can affect one’s energy levels, weight, blood pressure and overall quality of life.

Although PEGASI is not medically certified as a cure or treatment for insomnia, the research proves to be promising. Ninety-two percent of participants who wore the glasses for the prescribed amount of time reported an improvement in sleep. Additional research from NASA and some universities supports these findings. PEGASI’s unique wavelength of light treatment has the same positive effects on your body as natural light does. It helps regulate sleep and wakefulness.

Users will see changes in as little as seven days. With the brand new collapsible frame, PEGASI owners can enjoy light therapy anytime, anywhere. PEGASI features a built-in rechargeable li-polymer battery, Bluetooth 4.0, smart touch switch, patented flat laminating modules, and nose-pad camber for comfort.

To reap the full benefits of wearing PEGASI, those who diagnosed with insomnia and who are willing to improve the overall sleep quality are encouraged to keep them on for at least 30 minutes each day between the hours of 7 a.m. and 9 a.m. consecutively for 7 days. Progress can be monitored on a mobile device or smartphone using the PEGASI mobile app (IOS or Android). There are also options for energy boosts if the wearer feels sluggish or fatigued throughout the day.

To learn more about PEGASI Smart Sleep Glasses please visit GENHIGH at PEPCOM’s Digital Experience Metreon City View, 135 4th Street SF,CA, or at For an intimate demo session with GENHIGH please schedule an appointment with Minming Gu at or Gina Hughes at

About GenHigh
GenHigh’s a global personal electronics brand providing consumers worldwide high-quality, elegantly-designed smart devices engineered with the latest innovations in technology matched with precision craftsmanship. GenHigh’s commitment to research and development is reflected in every facet of our lifestyle products to bring consumers highly affordable quality devices. Headquartered in China, GenHigh was founded in 2017 with operations in San Francisco and Texas. For more information, please visit:

Gina Hughes
GenHigh Tech Co., Ltd
email us here

Source: EIN Presswire

Montreal Physician Warns New Yorkers Against Throwing Away Their Lives by Assisted Suicide

Happy to be alive

10 years ago wrongly told had few months to live, now able to spend time with grandchildren

Doctors wrong about the diagnosis of lung cancer

Assisted suicide laws in Canada and around the world are dangerous and not safe. People with years or decades to live are induced to throw away their lives.

Assisted suicide causes needless loss of lives around the world.People with years or decades to live are induced to throw away their lives.Assisted suicide proponents promote dying rather than living.”

— Dr. Paul Saba

NEW YORK, NY, USA, May 9, 2018 / — On May 3, 2018 Dr. Paul Saba spoke at the New York State Assembly Health Committee hearing on the assisted suicide bill – Assembly Bill A2383A.
Dr. Paul Saba is a family physician from Montreal, Canada and President of the Coalition of Physicians for Social Justice who has practiced both in the United States and Canada. He described the dangers and needless loss of lives caused by assisted suicide laws in Canada and around the world. During his testimony Dr. Saba warned : « Assisted suicide is dangerous and causes needless loss of lives in Canada and around the world. People with years or decades to live are induced to throw away their lives. Assisted suicide proponents promote dying rather than living.»

Thrown Away Lives: Nadine was diagnosed at 14 with a form of leukemia and could have given up after being told she would not survive even with treatment . The doctors were wrong. Today at 21 she is happy to be

Predictions of living less than 6 months are wrong in 50% of cases for severe heart or lung conditions. Ten years ago Mona was wrongly told she had a few months to live with a chronic lung condition . Today with better medical treatment she cares for and enjoys her grandchildren. Mona could have been a candidate for assisted suicide.

There are lethal errors in medical diagnosis. In 2004, Alexandre Montreuil underwent lung-removal surgery for a misdiagnosed lung cancer which was in fact a fungal infection cured with medicines. When first told of his lung cancer, he considered suicide. If Canada’s euthanasia and assisted suicide laws had been available in 2004, Alexandre would no longer be with us today.

Once assisted suicide is legalized for adults who are considered terminal, it quickly becomes legal for children, those with mental health problems and those without life ending illness as in Belgium and the Netherlands. Presently, Canada is studying extending assisted suicide and euthanasia to children who are “mature minors” and those with mental health problems. Children possibly as young as 11 or 12 could tragically see their lives ended prematurely without parental consent or prior notification. (Provincial-Territorial Expert Advisory Group on Physician-Assisted Dying, November 30, 2015)

Dr. Saba warned that: “People who are not well are often depressed and can be easily persuaded to prematurely end their lives. »

Euthanasia and assisted suicide are not “safe”. In Belgium, 1/3 of euthanasia deaths are performed without consent (CMAJ, June 15, 2010) and 1/2 of cases go unreported (BMJ, October 5, 2010).
In the province of Quebec, Canada, doctors euthanized 31 people without respecting the law out of the 638 in one year (Quebec End of life Commission 2017).

Most countries around the world including the United Kingdom and France have rejected euthanasia and assisted suicide laws because of the dangers to its citizens.

Dr. Saba reminded the New York State Assembly Health Committee that overly pessimistic doctors are less likely to admit patients with severe asthma to an intensive care unit. These patients are more likely to die (British Medical Journal 2007; 335:1132). “Won’t overly pessimistic and “burned out” doctors (15% of physicians are depressed) persuade people to die by assisted suicide rather than finding better treatments to live?” queried Dr. Saba.

Dr. Saba urged New Yorkers not to follow Canada’s dangerous and deadly example. He urged the NY Health Committee and legislature to vote against assisted suicide.

Dr. Paul Saba
Coalition of Physicians for Social Justice
email us here

Dr. Paul Saba testimony at New York State Assembly Health Committee hearing on the assisted suicide bill – Assembly Bill A2383A

Source: EIN Presswire

HIPAA Complaints in Past 5 Years Resulted in 7,100 OCR Enforcement Actions, Substantial Fines

HIPAA complaints are a less obvious way OCR enforces health privacy and security rules. Vendors, contractors and app developers must heed this customer power.

Patient complaints under HIPAA matter and have resulted in serious fines. About a dozen resolution agreements in the last five years originated with complaints and resulted in meaningful fines.”

— Dennis Melamed, Editor, Health Information Privacy/Security Alert

ALEXANDRIA, VA, US, May 9, 2018 / — Almost 7,100 patient and employee complaints forced organizations covered by HIPAA to make changes to their operations in the five-year period spanning from Jan. 1 2013 through Dec. 31,2017, according to the latest analysis by Health Information Privacy/Security Alert.

In 2013, 3,467 complaints filed with the HHS Office for Civil Rights (OCR) resulted in changes, according to the analysis by the independent trade newsletter. That was followed by 1,288 in 2014; 733, in 2015; 727 in 2016; and 863 in 2017.

That also included at least six resolution agreements which imposed of thousands of dollars in fines on HIPAA covered organizations.

And that is not counting the tens of thousands of actions the industry was required to take under the HITECH breach reporting and mitigation program.

“Patient complaints under HIPAA matter and have resulted in serious fines,” observed Dennis Melamed, editor and publisher of Health Information Privacy/Security Alert. “About a dozen resolution agreements in the last five years originated with complaints and resulted in meaningful fines.”

The HIPAA complaint system is just one way in which healthcare organizations are under tighter supervision than other sectors and have made more changes than many other sectors.

A fuller discussion of the less obvious ways HIPAA is being enforced will be held in a May 24 webinar: The Hidden World of OCR’s HIPAA Enforcement. In the 90-minute program, national HIPAA authorities will brief participants on the lessons learned from OCR’s complaint system, HITECH small breaches, OCR’s technical assistance program and what the rejected complaints can tell us about patient concerns about the Internet of Medical Things.

For more information and to register, visit

Katalin Sugar
Melamedia, LLC
email us here

Source: EIN Presswire

Dallas Celebrates Corporate Wellness at 2018 Spring Fit Company Challenge

Teams from companies in Dallas show the impact of their wellness programs by training for and conquering a 3-course fitness challenge hosted by Fit Company.

DALLAS, TEXAS, USA, May 9, 2018 / — On April 28, 2018 participants from companies located in the Dallas area took part in the Fit Company Challenge, a corporate wellness event hosted by the Fit Company Institute. The challenge provided area companies an opportunity to come together as a team and spend a morning exercising, pushing their physical and mental limits and showing the importance of living a healthy lifestyle. Companies split their team into squads of 3 to 4 people who worked together to complete a variety of fitness stations to challenge their fitness level and earn points for their company. Teams chose what level to go through each course which allowed participants of all fitness levels to push their physical fitness without going too far out of their comfort zone.

On event date, volunteers assisted the contenders through the courses from FITNZ 360 ( Participants challenged their strength, conditioning, power, agility, and ended with a test of endurance to show their companies and colleagues that they practice what they preach.

The challenge was held at Flag Pole Hill Park, located a short drive from downtown Dallas.

The following is a list of the top finishers in Dallas that participated in the 2018 Fit Company Challenge:

Top Companies by Division

Large Division
2) Pegasus Logistics
3) Legacy Texas

Medium Division
1) Call Box
2) United Way of Metropolitan Dallas

Small Division
1) Riveron Consulting
2) Amino Transport
3) Austin Commercial
4) QuestPro

Micro Division
1) Eric L. Davis Engineering
2) C1S Group, Inc.

Top Teams Overall (Based on Total Points)

1) C1S Group, Inc. – #2284
2) Pegasus Logistics – #2302
3) defi SOLUTIONS – #2322
4) Call Box – #2340
5) Pegasus Logistics – #2307 (Tie)
5) Riveron Consulting – #2324 (Tie)
5) Call Box – #2338 (Tie)
8) Amino Transport – #2295
9) Riveron Consulting – #2323
10) Call Box – #2336
11) defi SOLUTIONS – #2317 (Tie)
11) Call Box – #2337 (Tie)
13) defi SOLUTIONS – #2320 (Tie)
13) Riveron Consulting – #2325 (Tie)
15) Pegasus Logistics – #2304

Top Teams By Course

Course 1 – Level 2

1) #2340 – Call Box
2) #2336 – Call Box
3) #2302 – Pegasus Logistics
4) #2284 – C1S Group, Inc.

Course 1 – Level 1

1) #2295 – Amino Transport
2) #2307 – Pegasus Logistics
3) #2335 – Call Box
4) #2317 – defi SOLUTIONS

Course 2 – Level 2

1) #2284 – C1S Group, Inc.
2) #2302 – Pegasus Logistics (Tie)
2) #2322 – defi SOLUTIONS (Tie)
4) #2338 – Call Box

Course 2 – Level 1

1) #2307 – Pegasus Logistics
2) #2318 – defi SOLUTIONS
3) #2314 – defi SOLUTIONS (Tie)
3) #2320 – defi SOLUTIONS (Tie)

Course 3 – Level 2
1) #2338 – Call Box
2) #2325 – Riveron Consulting
3) #2284 – C1S Group, Inc. (Tie)
3) #2322 – defi SOLUTIONS (Tie)
3) #2324 – Riveron Consulting (Tie)
3) #2334 – Legacy Texas (Tie)

Course 3 – Level 1
1) #2295 – Amino Transport
2) #2307 – Pegasus Logistics
3) #2335 – Call Box
4) #2290 – United Way of Metropolitan Dallas (Tie)
4) #2299 – Eric L. Davis Engineering (Tie)
4) #2317 – defi SOLUTIONS (Tie)

Matt Barker
Fit Company Institute
email us here

Source: EIN Presswire

Dr. Henry Grayson to be Featured on CUTV News Radio

WESTPORT, CONNECTICUT, UNITED STATES, May 9, 2018 / — Our thoughts are powerful acts of creation: we have the power to make ourselves sick; we have the power to make ourselves well; the power to destroy relationships and the power to heal and deepen them; the power to block success and the power to create success. To live the healthy life we truly want to live, we must change our negative belief systems through any and all means available and clear out painful encodings in our brain that caused them.

Dr. Henry Grayson is an integrative and holistic mind-body psychotherapist.

“It's always been my intention to help people,” says Dr. Grayson. “I'm responding to their particular feelings, their needs, their pains, what their goals are, to connect with what they are experiencing. The whole purpose of the work I do is to help people embrace their intrinsic power to be at peace and be happy, healthy and successful.”

Dr. Grayson employs a synergistic approach that goes beyond traditional talk therapy. According to Dr. Grayson, psychoanalysis is valuable in the sense that it puts us in touch with the power of the subconscious mind. We just need to find more ways of accessing it and changing the parts we do not wish to keep.

“Even the best therapist will admit traditional psychoanalysis doesn't really cover everything for everyone. It didn't cover even my own personal growth issues,” says Dr. Grayson. “I learned there are other methods that help with different kinds of issues, but no one method covers it all. That inspired the whole direction of my career: learning a variety of modalities and seeing what works best depending on the patient.”

In this way, Dr. Grayson can be the right therapist for anyone by adapting to your needs. In addition to his training in traditional psychotherapy, Dr. Grayson can also incorporate the new evidence-based modalities like EMDR and EFT into a session to clear traumas or negative beliefs more deeply and quickly.

“It’s hard to hang a picture on the wall if you don't have a hammer and a nail. We can all benefit from more tools to help us, and energy psychology tools are helpful,” says Dr. Grayson. “You start with wherever there's a crack in that door. And then you work where a person is ready to go. That inspires them to be open to other places

“I tend to be more curious. It’s quite common for therapists to grow attached to the system they were trained in. I think we have to work on multiple levels if we really want growth for our patients and ourselves.”

Dr. Grayson’s is the author of Mindful Loving and The New Physics of Love. His most recent book is Your Power To Heal

“The tools I use for physical healing are the same tools that can be used in healing relationships. They can be used to deal with blocks to your success and accomplishments in the world. We need to deal with them on all these different levels: the genes, the genetic memories, the early traumas, the unremembered ones, then the remembered ones. We've got to change our old beliefs and install new beliefs that are positive and support you and eliminate negative downloads from our parents and increase the positive ones."

CUTV News Radio will feature Dr. Henry Grayson in an interview with Doug Llewelyn on May 11th at 2pm EDT and with Jim Masters on May 18th at 2pm EDT.

Listen to the show on BlogTalkRadio. If you have a question for our guest, call (347) 996-3389.

For more information on Dr. Henry Grayson, visit

Lou Ceparano
(631) 850-3314
email us here

Source: EIN Presswire

CVR & U.S. FDA: A Meeting of the Minds

CVR – CSS Device

CVR Medical Corp (OTCQB:CRRVF)

VANCOUVER, BC, CANADA, May 9, 2018 / — Concludes De Novo Pathway Best Suited

CVR Medical Corp. (CVM.V) (TSXV: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) ("CVR Medical”) announces the receipt of official meeting minutes for their Pre-Submission meeting on March 23, 2018 with the U.S. Food and Drug Administration (FDA) regarding the Carotid Stenotic Scan (CSS) device and it’s upcoming FDA submission for market release. Attendees of the meeting included CVR management, regulatory consultant’s Duval & Associates, and key reviewers from the FDA. The purpose of the meeting was to receive feedback and define the necessary regulatory pathway, clinical trial substantiation requirements, and device testing.

Based on prior communication with the FDA and input provided by key regulatory advisors, CVR had considered the potential for either a 510k, De Novo, or PMA submission; with the De Novo being the preferred pathway. During the meeting these topics were discussed and in follow-up communication the FDA team stated the CSS was sufficiently different from other devices on the market today to decide the De Novo pathway was best suited, which is designed for low to moderate risk novel devices.

CVR COO Tony Robinson states, “The pre-submission meeting went as expected. The CVR leadership team had quality dialog with the FDA reviewers, resulting in meaningful clarity and understanding of the project for both sides. We truly value the FDA’s input, alleviating much of the concern stemming from questions about the direction and pathway of the project. Upon further discussion, we understand the clinical trial requirements will fall within the previously expected range. Altogether, I believe we align with the FDA on this undertaking, and CVR is poised for our upcoming submission and subsequent approval.”

Mark DuVal, President of Duval & Associates, who was also present at the meeting stated, “Communications with FDA regarding the CSS device to date have been very collaborative and responsive. Our firm believes that the De Novo program will provide the most efficient pathway to US commercialization of the CSS device. We also believe the FDA has accepted our argument that the CSS represents a lower risk device than standard Doppler Ultrasound. This will reduce data requirements. Now we move into a phase of offering FDA proposed ‘special controls’ which are tests we propose to conduct to address these risks, albeit low risks, of using this device.”

CVR Chief Executive Officer, Peter Bakema, expands upon the FDA’s decision as it applies to the overall project, “While every member of our team and board are excited about the FDA’s observation that our CSS Device has no predicate, due to the continual evolution of this project, this exciting development does require us to extend our previously stated guidance regarding our targeted submission date. With the De Novo process and associated factors comes a much higher level of documentation and testing requirements. Due to these vital elements we feel it necessary to extend our projected submission timeline another 60 to 90 days. Both myself and team have already taken the actions to mitigate this addition to the timeline. We anticipate an end of Q3 submission, and will update our timeline as we move closer.”

For additional information on the organization, leadership, and current news please visit the company website

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Marc S. Lubow.
Vice President Capital Markets, Investor Relations
Telephone: (403) 262-9888
Brisco Capital Partners Corp.
Scott Brisco, President
Telephone: (403) 262-9888

Peter Bakema
CVR Medical Corp.
email us here

Source: EIN Presswire